Print Page   |   Report Abuse   |   Sign In   |   Join UPhA
News & Press: Advocacy

FDA requiring lower starting dose for sleep drug Lunesta

Thursday, May 15, 2014   (0 Comments)
Posted by: Shannon Glaittli
Share |

The U.S. Food and Drug Administration today announced it required the manufacturer of the sleep drug Lunesta (eszopiclone) to change the drug label and lower the current recommended starting dose. Data show that eszopiclone levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving, even if they feel fully awake.


Community Search
Sign In


Calendar

10/29/2020 » 10/30/2020
UPhA 2020 Annual Convention and Exposition